com

Indevus Pharmaceuticals is a biopharmaceutical company engaged in
the acquisition, development and commercialization of products
targeting certain medical specialty areas, including urology and
infectious diseases.digene. For
more information, visit the company 's Web site, http://www.

genital cold

is a biopharmaceutical management company
that employs an "essential product development" paradigm to enhance
the development process of early stage drugs and combination products . The
participant passcode is 27496849.com.

genital health

The first patient has
already been dosed, and the Company anticipates completing treatment
in 2006. The Company will hold a conference call
and web cast to discuss these results at 9:00 a.

health treat

sexually skin

The trial will study the safety
and efficacy of a single application of acyclovir cream using
Transport's drug-delivery system tested against placebo and a
conventional formulation that requires multiple applications each day
for several days. The study is
designed to demonstrate superiority over the current topical antiviral
standard of care. The study
will conclude after approximately 200 patients in each treatment arm
have presented symptoms and been treated. eastern time on May
10, 2005.com.

related health

to market and sell our system. (NASDAQ: IDEV) will announce its second quarter
fiscal 2005 financial results in a press release to be issued before
market open on May 10, 2005. and Canada, and 617-614-4910 from international locations. A replay of the call will be
available beginning at 11:00 AM on May 10, 2005 and lasting until
12:00 AM on May 30, 2005. The company's hc2 High-Risk HPV DNA
Test(TM) is the only test for human papillomavirus approved by the FDA, and is
approved for both follow-up evaluation in women with inconclusive Pap results
and for primary adjunctive screening with the Pap test in women age 30 and
older.

treat related

, president and chief operating
officer of Transport. The
pre-filled cartridges contain a unit dose of drug. The study also has several secondary endpoints, one of
which will measure the treatment's ability to prevent full-blown
lesions from occurring.

About Transport's Acyclovir Product

Transport 's oral herpes product delivers acyclovir, an approved
treatment for cold sores, directly to impacted skin at concentrations
up to 40 times higher than topical formulations.

About Transport Pharmaceuticals , Inc. GAITHERSBURG, Md.thehpvtest.

treatment soap

D.

NeXus therapeutics, inc.
The press release and the live web cast will be accessible by
visiting the Investors section of the Company's website,
http: //www.
A link to Deutsche Bank's live webcast and recording of Digene's
presentation will be available on the Company's website,
http://www.

herpes soap

Pharmaceutical Writers/Business Editors/Health /Medical
Writers/Biotech Writers
BIOWIRE2K

PHILADELPHIA + FRAMINGHAM, Mass.

About neXus therapeutics, inc.m. and Canada, and 617-801-6888 from
international locations, using the passcode 84508753. These brand names do not refer to the
Digene product that tests for several types of the virus commonly referred to
as "low-risk HPV," which are not associated with cervical cancer.

genital wisdom

"We are initiating this Phase III trial based on positive clinical
data generated by our Phase II study with acyclovir, which
demonstrated that rapid delivery of high doses of the medication
significantly reduces the duration of the cold sore lesions,"
explained Dennis I."
Transport's platform is based on iontophoresis, a technology
employing a low-voltage electrical charge to increase skin
permeability in order to locally deliver medication through the skin.
The trial will be conducted in three arms: in the first arm,
patients will receive Transport's device/drug system with an acyclovir
cartridge; in the second arm, patients will receive the device/drug
system with a placebo cartridge; and the in the third open-label arm,
patients will use a conventional acyclovir (Zovirax(R)) cream therapy . This conference
will be held at The Hyatt Regency Hotel in Baltimore, Maryland.

herbal wisdom

For more information, please visit www.transportpharma.
The live call may be accessed by dialing 800-591-6944 from the
U.

Digene to Present at Deutsche Bank's 30th Annual Health Care Conference

For more
information, visit http://www.

sores transmitted

The Company has developed a small, wireless electrode and medication
applicators that will allow patients to self-administer topical drugs
for a variety of indications .
In addition, Transport's product requires only one ten-minute
application, compared with available formulations that require up to 5
daily applications for 4 to 5 days.----Indevus
Pharmaceuticals , Inc.

About Digene:
Digene Corporation (Nasdaq: DIGE), based in Gaithersburg, MD, develops,
manufactures and markets proprietary DNA and RNA testing systems for the
screening, monitoring and diagnosis of human diseases -- with a focus on
women's cancers and infectious diseases .

skin daily

All 24 clinical sites will be opened in the United States.

herpes prevention

This study will test the
efficacy and safety of this new treatment paradigm.

Indevus Pharmaceuticals to Announce Second Quarter Fiscal 2005 Financial Results on May 10 2005; Company to Conduct Conference Call and Web Cast

To access the replay, please dial
888-286-8010 from the U. The recording of Digene's presentation will be
available beginning on the evening of May 4, 2005, until approximately July 4,
2005.

treat transmitted

The system consists of a reusable
control unit and disposable, single-use medicated cartridges. The
patient will visit the clinic for daily follow-up evaluations for 5 to
10 days following treatment.
Enrollment is currently open and the Company expects it will have
to recruit 1,800 patients in order to treat the needed 600.

sores skin

"Since the conclusion of that clinical study, we
have completed the design and manufacture of a unit-drug cartridge and
a control unit that allows the patient to initiate and administer
treatment at first signs and symptoms. This approach
addresses the challenge of rapidly achieving clinically active
concentrations of treatment in the skin necessary to treat the virus -
a barrier that limits the efficacy of available oral herpes therapies.D.com. An archived version of the call will be
accessible at the same web address for 30 days following the live
call.com.

wisdom sores

The Company's lead product enables the delivery of high
doses of acyclovir, an approved cold sore treatment, directly to
impacted skin areas, addressing a primary barrier to effective
treatment of herpes labialis.S.

pure treatment

Study Design

This Phase III study is a multi-centered, double blind,
placebo-controlled trial testing Transport's device/drug combination
product for the delivery of acyclovir, an approved medication to treat
cold sores, in patients with recurrent herpes labialis lesions (cold
sores ).

lip conditions

The initiation of this Phase III study positions us
to expand our business development efforts for this indication and
find a partner in the U.S.

treat infections

Transport Pharmaceuticals Initiates Phase III Trial in Cold Sore Indication with Its Device/Drug Combination

----

Phase II Data Have Demonstrated Therapy Reduces Healing Time with
a Single Treatment

Transport Pharmaceuticals, Inc. (Transport ) announced today that
it has initiated a Phase III trial using its device/drug combination
product for the delivery of acyclovir. Goldberg, Ph. The Company operates under the
management of neXus therapeutics , inc.
NeXus was founded by Dennis I.

prevention both

, a broadly experienced
drug development executive, and employs a team of highly skilled
chemistry, manufacturing, regulatory and development executives.indevus .

Except for the descriptions of historical facts contained herein,
this press release contains forward-looking statements that involve
risks and uncertainties that could cause the Company's actual results
and financial condition to differ materially from those anticipated by
the forward-looking statements.

cold pure

At first signs and/or symptoms of a recurrent herpetic episode, the
patient will check in with the study center clinic to confirm the
lesion and will be instructed to begin treatment immediately . Goldberg, Ph.

Pharmaceutical Writers/Business Editors

LEXINGTON, Mass. These risks and uncertainties are set
forth in the Company's filings under the Securities Act of 1933 and
the Securities Exchange Act of 1934 under "Risk Factors" and
elsewhere, and include, but are not limited to: dependence on the
success of SANCTURA(R) and SANCTURA XR(R); the early stage of products
under development; uncertainties relating to clinical trials,
regulatory approval and commercialization of our products,
particularly SANCTURA and SANCTURA XR; risks associated with
contractual agreements , particularly for the manufacture and
co-promotion of SANCTURA and SANCTURA XR; dependence on third parties
for manufacturing and marketing; competition; need for additional
funds and corporate partners, including for the development of our
products; failure to acquire and develop additional product
candidates; history of operating losses and expectation of future
losses; product liability and insurance uncertainties; risks relating
to the Redux-related litigation; limited patent and proprietary
rights; dependence on market exclusivity; valuation of our Common
Stock; risks related to repayment of debts; risks related to increased
leverage; and other risks.

cold wisdom

The trial's primary endpoint measures the duration of the
herpes lesions. is developing a proprietary
electrokinetic drug delivery technology applicable to multiple
dermatological diseases, with an initial focus on herpes labialis, or
cold sores.

organic herbal

S., Digene Corporation
(Nasdaq: DIGE), today announced that Charles Fleischman, President and Chief
Financial Officer, will be presenting at Deutsche Bank's 30th Annual Health
Care Conference on Wednesday, May 4, 2005 at 9:30 AM (EDT).digene.

related treatment

Transport Pharmaceuticals, Inc. The Company currently markets SANCTURA(R) for
overactive bladder and has multiple compounds in clinical development ,
including PRO 2000 for the prevention of infection by HIV and other
sexually transmitted pathogens , pagoclone for stuttering, aminocandin
for systemic fungal infections, and IP 751 for interstitial cystitis. For primary adjunctive screening, it is marketed as both The Digene
HPV Test and the DNAwithPap (TM) Test. Digene's product portfolio also
includes DNA tests for the detection of other sexually transmitted infections,
including chlamydia and gonorrhea, as well as tests for blood viruses.